Clinical Trials on Libido in Switzerland

Total 62 results

University Hospital Inselspital, Berne
University of Zurich; University Hospital Muenster

Completed

Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women (CAG-Libido)

Polymorphism, Genetic | Libido | Receptors, Androgen | Androgen Effect

Switzerland
University of Lausanne

Completed

Acute Effect of Fructose on Lipid Metabolism and Gender Differences

Lipid Metabolism

Switzerland
Center for Primary Care and Public Health (Unisante)...
Swiss Heart Foundation

Completed

Cascade Genetic Testing of Familial Hypercholesterolemia (CATCH)

Familial Hypercholesterolemia

Switzerland
Novartis

Completed

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Mixed Dyslipidemia | Heterozygous Familial Hypercholesterolemia

Switzerland
University Hospital Inselspital, Berne
Takeda

Completed

Physiologic Plasticity of Intramyocardial Lipid Storage

Lipid Metabolism

Switzerland
University Hospital, Basel, Switzerland

Completed

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Metabolic Syndrome | Familial Combined Hyperlipidemia | Familial Hypertriglyceridemia

Switzerland
Centre Hospitalier Universitaire Vaudois
Agroscope Liebefeld-Posieux Research Station ALP

Completed

Effects of a Probiotics on the Health of Normal Young Males (FFF)

Inflammation | Dyslipidemia

Switzerland
University of Zurich

Completed

Pulmonary Involvement in Patients With Fabry Disease

Fabry Disease

Switzerland
University of Lausanne
University Hospital Inselspital, Berne; Centre Hospitalier Universitaire Vaudois

Completed

Reduction of Sweetened Beverages and Intrahepatic Fat (REDUCS)

Obesity | Metabolic Syndrome | Dyslipidemia

Switzerland
Albina Nowak, MD
Swiss National Science Foundation

Recruiting

Effect of Cannabinoids on Pain in Fabry Disease Patients

Pain, Neuropathic

Switzerland
Novartis

Completed

A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Hypercholesterolemia | Essential Hypertension

Switzerland, Germany
Novartis

Completed

Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome

Dyslipidemia

Germany, Switzerland
University Hospital Inselspital, Berne

Terminated

The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism (Hydrocort)

Hypopituitarism | Insulin Sensitivity | Hydrocortisone | Lipids | Fatty Acids, Nonesterified

Switzerland
University of Basel
University of Lausanne; Technical University of Munich

Recruiting

Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial (SphingoFIT)

Cardiovascular Diseases | Dyslipidemias | Blood Pressure | Overweight and Obesity | Metabolic Disease

Switzerland
University Hospital Inselspital, Berne
Swiss National Science Foundation

Completed

The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.

Growth Hormone Deficiency | Insulin Sensitivity | Aerobic Exercise | Ectopic Lipids | Fat Load

Switzerland
Clarunis - Universitäres Bauchzentrum Basel

Recruiting

Different Limb Lengths in Gastric Bypass Surgery (SLIM)

Hypertension | Diabetes Mellitus, Type 2 | Dyslipidemias | Sleep Apnea | Obesity, Morbid

Switzerland
University of Zurich

Completed

Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.

Fabry Disease

Switzerland
Spital Linth
University of Zurich; National University, Singapore

Unknown

Lipidomics and Functional Analyses of Platelets in Fabry Disease

Fabry Disease

Switzerland
University of Lausanne Hospitals
Salk Institute for Biological Studies

Completed

Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome

Obesity | Metabolic Syndrome | Dyslipidemias | Glucose Intolerance | Eating Behavior | Steatosis of Liver

Switzerland
Foundation for Cardiovascular Research, Zurich
Bristol-Myers Squibb

Completed

Effect of Atazanavir on Endothelial Function in HIV-Infected Patients (ENDOPACT)

HIV Infections | Dyslipidemia

Switzerland
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

Hyperlipidemia

Switzerland
Sanofi

Terminated

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Obesity | Dyslipidemias

Germany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
Alexion Pharmaceuticals

Completed

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD)

United States, United Kingdom, France, Canada, Czech Republic, Italy, Poland, Switzerland
University of Ulm
University of Pisa; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaborators

Recruiting

Registry for Patients With Lipodystrophy (ECLip Registry)

Lipodystrophy Acquired | Lipodystrophy Congenital

Austria, France, Germany, Hungary, Italy, Portugal, Spain, Netherlands, Russian Federation, Slovenia, Switzerland, Turkey, United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Atorvastatin Three Year Pediatric Study

Familial Hypercholesterolemia

United States, Spain, Turkey, Canada, Belgium, Germany, Greece, Hungary, Italy, Norway, Poland, Puerto Rico, Russian Federation, Slovakia, Switzerland
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Idorsia Pharmaceuticals Ltd.

Completed

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 (RETRIEVE)

GM2 Gangliosidosis | GM1 Gangliosidosis | Tay-Sachs Disease | Sandhoff Disease | Gaucher Disease, Type 2 | AB Variant Gangliosidosis GM2

United States, Spain, Germany, Italy, Belgium, Brazil, France, Portugal, Switzerland, United Kingdom
KemPharm Denmark A/S

Completed

A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C

Spain, France, United Kingdom, Switzerland, Denmark, Poland, Italy, Germany
IntraBio Inc

Active, not recruiting

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C

United States, Australia, United Kingdom, Germany, Slovakia, Netherlands, Czechia, Switzerland
Amgen

Terminated

Study to Evaluate the Safety of Repatha® in Pregnancy

Pregnancy | Hypercholesterolaemia

Belgium, Denmark, Italy, Czechia, United Kingdom, Australia, Austria, Greece, Switzerland, Netherlands, Spain, Sweden, Slovakia, Norway
Amgen

Completed

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) (HAUSER-OLE)

Familial Hypercholesterolemia

Canada, Italy, Norway, Belgium, United States, Turkey, Australia, Austria, South Africa, Poland, Switzerland, Spain, Portugal, Slovenia, Brazil, Russian Federation, Hungary, United Kingdom, Colombia, Czechia, Netherlands, Greece, Ma...
Novartis Pharmaceuticals

Recruiting

Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL)

Mixed Dyslipidemia | Primary Hypercholesterolemia

Switzerland, United Kingdom, Saudi Arabia, United Arab Emirates, Austria, Israel, China, Malaysia
Sanofi

Completed

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Obesity | Dyslipidemia

United States, Canada, Australia, Italy, Spain, Sweden, Switzerland, Finland
ZevraDenmark

Active, not recruiting

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C

United States, Spain, United Kingdom, Denmark, France, Germany, Italy, Poland, Switzerland
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (V-PEDS-OLE)

Heterozygous or Homozygous Familial Hypercholesterolemia

Netherlands, Israel, Hungary, Italy, Germany, Turkey, Spain, United States, France, Norway, Russian Federation, South Africa, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, Poland, Taiwan, Malaysia
University Hospital, Basel, Switzerland
Bristol-Myers Squibb; Swiss National Science Foundation

Completed

Cardiovascular Risk Factor Management in HIV Infection

HIV Infection | Dyslipidemia | Coronary Heart Disease | Diabetes Mellitus, Non-Insulin-Dependent

Switzerland
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
Novartis Pharmaceuticals

Active, not recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16)

Familial Hypercholesterolemia - Heterozygous

United States, Germany, South Africa, Greece, Italy, Czechia, Taiwan, Slovakia, Turkey, France, Russian Federation, Canada, Spain, Jordan, Switzerland, Hungary, Poland, Netherlands, Norway, United Kingdom, Lebanon, Argentina, Brazil, ... and more
Amgen

Completed

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Heterozygous Familial Hypercholesterolemia

United States, Canada, Italy, Norway, Belgium, Turkey, Australia, New Zealand, Austria, Czechia, South Africa, Poland, Spain, Switzerland, Netherlands, Taiwan, Finland, Brazil, Portugal, Slovenia, Russian Federation, Hungary, United... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Hypercholesterolemia

France, Belgium, Austria, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)

Fabry Disease

United States, Netherlands, Hungary, United Kingdom, Czechia, Norway, Slovenia, Spain, Finland, France, Italy, Switzerland
Idorsia Pharmaceuticals Ltd.

Active, not recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Fabry Disease

United States, United Kingdom, Norway, Germany, Australia, Canada, Spain, Switzerland, Austria, Belgium, France, Netherlands, Poland
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more
Amgen

Completed

Chart Review of Repatha® in Subjects With Hyperlipidaemia (HEYMANS)

Hypercholesterolaemia

Austria, Italy, Belgium, Czechia, Switzerland, Spain, Slovakia, Germany, Portugal, Greece, Bulgaria, Sweden
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Hypercholesterolaemia

Belgium, Spain, Germany, Austria, Italy, United States, France, Netherlands, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)

Fabry Disease

United States, Spain, Belgium, Australia, Austria, Canada, Germany, Ireland, Italy, Netherlands, Norway, Poland, Switzerland, United Kingdom
Afimmune

Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)

Type 2 Diabetes | Hypertriglyceridemia

Georgia, United States, Germany, Israel, Latvia, Switzerland
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico

Clinical Trials on Libido in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations